Alliancebernstein L.P. lowered its stake in shares of Advaxis, Inc. (NASDAQ:ADXS) by 13.3% during the first quarter, Holdings Channel reports. The fund owned 46,900 shares of the biotechnology company’s stock after selling 7,200 shares during the period. Alliancebernstein L.P.’s holdings in Advaxis were worth $383,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ADXS. Vident Investment Advisory LLC increased its stake in Advaxis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 108,941 shares of the biotechnology company’s stock valued at $890,000 after buying an additional 18,156 shares during the period. American International Group Inc. increased its stake in Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 1,459 shares during the period. SG Americas Securities LLC increased its stake in Advaxis by 2.9% in the first quarter. SG Americas Securities LLC now owns 49,333 shares of the biotechnology company’s stock valued at $403,000 after buying an additional 1,398 shares during the period. Stevens Capital Management LP bought a new stake in Advaxis during the first quarter valued at about $105,000. Finally, Parametric Portfolio Associates LLC increased its stake in Advaxis by 116.3% in the first quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock valued at $707,000 after buying an additional 46,559 shares during the period. 54.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Advaxis, Inc. (NASDAQ ADXS) traded up 3.13% during mid-day trading on Friday, hitting $6.26. The company’s stock had a trading volume of 378,179 shares. The company has a 50-day moving average of $6.63 and a 200 day moving average of $7.88. Advaxis, Inc. has a 1-year low of $5.70 and a 1-year high of $15.10. The company’s market cap is $253.29 million.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/12/advaxis-inc-adxs-position-cut-by-alliancebernstein-l-p.html.

Several analysts recently weighed in on ADXS shares. BidaskClub downgraded Advaxis from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. ValuEngine downgraded Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the company a “buy” rating in a research note on Thursday, July 6th. Finally, HC Wainwright set a $23.00 target price on Advaxis and gave the company a “buy” rating in a research note on Wednesday, June 14th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Advaxis currently has a consensus rating of “Hold” and an average price target of $22.00.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis, Inc. (NASDAQ:ADXS).

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.